Month: April 2018

Join Us at CSCC 2018 in Ottowa!

Canadian Society for Clinical Chemists (CSCC) 2018 BUHLMANN Diagnostics Corp  Booth: #410 June 03 - 06, 2018 | Fairmont Château Laurier Hotel. | Ottawa, ON Learn More Come by our booth to get an update on our Calprotectin,Therapeutic Drug Monitoring, Chemistry, Neuroimmunology, and Cellular Allergy portfolios Calprotectin and TDM: IBDoc®, the ONLY in-vitro diagnostic POC and home testing
Continue Reading

Connect with BUHLMANN at DDW 2018

Digestive Diseases Week (DDW) 2018 BUHLMANN Diagnostics Corp  Booth: #2347 June 02-05, 2018 | Walter E. Washington Convention Center | Washington, DC Learn More Come by our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP and serum infliximab trough levels  (Additional trough level
Continue Reading

The Clinical Utility of Basophil Activation Testing in Diagnosis and Monitoring of Allergic Disease

Chronic Urticaria and BAT Guidelines: Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, Rouzaire P, Ebo DG, Sabato V, Sanz ML, Pecaric-Petkovic T, Patil SU, Hausmann OV, Shreffler WG, Korosec P, Knol EF. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015 Nov;70(11):1393-405. Epub
Continue Reading

The EAACI/GA(2) LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria

Chronic Urticaria and BAT Guidelines: Zuberbier T, et al;; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul;69(7):868-87.  Epub 2014 Apr 30. PubMed PMID:
Continue Reading